Infectious Disease

Gates MRI starts Phase III trial for tuberculosis vaccine

The Bill & Melinda Gates Medical Research Institute (Gates MRI) has dosed the first patient cohort in a Phase III…

TB potentially transmissible in undiagnosed cases

Tuberculosis (TB) is one of the oldest infectious diseases known to man and one of the “big three” [along with…

Merck to start trials investigating single dosing regimen of HPV vaccine

Merck & Co (MSD) plans to start two prospective clinical trials evaluating the safety and efficacy of a single-dose regimen…

Cases of tuberculosis could exceed pre-pandemic numbers in England

Tuberculosis (TB) is a bacterial infection that predominantly affects the lungs, and despite being preventable and treatable, TB remains one…

Replicate’s rabies vaccine demonstrates effectiveness in Phase I trial

US-based biotech Replicate Bioscience has announced positive preliminary data where its self-replicating RNA (srRNA) rabies vaccine, RBI-4000 achieved a strong…

Addimmune to investigate HIV gene therapy without SOC in Phase Ib trial

Addimmune will be launching a Phase Ib trial investigating its human immunodeficiency virus (HIV) candidate AGT103-T to review its safety…

Curevo looks to challenge GSK’s Shingrix with positive Phase II data

Curevo Vaccine’s varicella-zoster virus vaccine amezosvatein has achieved all primary endpoints, including demonstrating non-inferiority to GSK’s Shingrix in a Phase…

Inventprise completes dosing in Phase II pneumococcal vaccine study

Inventprise has completed vaccine administration in a Phase II study investigating the dosing range of its 25-valent pneumococcal conjugate vaccine…

Recibo’s shingles vaccine shows positive safety profile in Phase I trial

China-based Jiangsu Recbio Technology has announced positive results from a first-in-human (FIH) trial of a shingles vaccine. The trial compared…

Shionogi commences Phase III monovalent Covid-19 vaccine trial 

Shionogi has commenced a Phase III clinical trial analysing additional doses of its monovalent Covid-19 vaccine against the XBB1.5 strain…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close